Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes

doi:10.5312/wjo.v6.i1.62

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10245)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

632

WORD

268

HTML

6766

Figures (1-2)

153

Tables (1-8)

124

Sum=7943

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1030

Download

1272

Sum=2302

Jan 18, 2015 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (90)

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Orthop. Jan 18, 2015; 6(1): 62-76
Published online Jan 18, 2015. doi: 10.5312/wjo.v6.i1.62

Table 1 Prevalence of previous cardiovascular events in patients with and without diabetic foot

	Pts with diabetic foot (n = 102) <	Pts without diabetic foot (n = 123)	P
CAD (%)	33 (32.3)	24 (19.5)	0.0043
TIA (%)	15 (14.7)	9 (7.3)	< 0.0001
Stroke (%)	18 (17.6)	11 (8.9)	< 0.05
Stroke toast subtypes
LAAS	6 (33.3)	5 (45.4)
Lacunar	12 (66.6)	6 (54.5)
CEI	0	0
Diabetic retinopathy (%)	55 (53.9)	47 (38.2)	< 0.0001
Renal failure (%)	6 (5.8)	7 (5.6)	NS

Modified from Pinto et al[19]. CAD: Coronary artery disease; TIA: Transient ischemic attack; LAAS: Large artery atherosclerotic stroke; CEI: Cardioembolic.

Table 2 Cox regression analysis of demographic and clinical variables associated with cardiovascular morbidity n (%)

	Pts with diabeticfoot(n = 102)	Pts without diabetic foot(n = 123)	P
CAD	12 (11.7)	7 (5.6)	< 0.005
Angina	4 (3.9)	3 (2.4)	< 0.005
Myocardialinfarction	8 (7.8)	4 (3.5)	< 0.001
TIA	6 (5.8)	4 (3.2)	< 0.0001
Stroke	7 (6.8)	5 (4.0)	< 0.005
Renal failure	4 (3.9)	5 (4)	NS
Deaths	14 (13.7)	10 (8.1)	< 0.005
Cardiovascular cause	13 (12.7)	9 (7.3)	< 0.005
AMI	(3.9)	1 (0.81)	NS
Stroke	3 (2.9)	2 (1.6)
CHF	3 (2.9)	3 (2.4)
Other vascular cause	3 (2.9)	3 (2.4)
Other cause	1 (0.9)	1 (0.81)

From Pinto et al[19]. CAD: Coronary artery disease; TIA: Transient ischemic attack; AMI: Acute myocardial infarction; CHF: Congestive heart failure.

Table 3 Previous cerebro-vascular events in patients with and without diabetic foot

	Diabetic foot(n = 102)	No diabetic foot (n = 123)	P
TIA	15 (14.7)	9 (7.3)	< 0.0001
Ischemic stroke	18 (17.6)	11.8 (8.9)	< 0.0001
Stroke toast subtype
LAAS	6 (33.3)	5 (45.4)	< 0005
LAC	12 (66.6)	6 (54.5)	< 0.005
CEI	0	0

From Pinto et al[20]. TIA: Transient ischemic attack; LAAS: Large artery atherosclerotic stroke; LAC: Lacunar stroke; CEI: Cardioembolic.

Table 4 Incidence of stroke at follow-up in subjects with and without diabetic foot

	Diabetic foot(n = 102)	No diabetic foot(n = 123)	P
TIA	6 (5.8)	4 (3.2)	< 0.0001
Ischemicstroke	7 (6.8)	5 (4.0)	< 0.005
LAAS	4	3	< 0.005
LAC	3	2	< 0.005
CEI	0	0	NS

From Pinto et al[20]. TIA: Transient ischemic attack; LAAS: Large artery atherosclerotic stroke; LAC: Lacunar stroke; CEI: Cardioembolic.

Table 5 General and demographic variables in cases and controls n (%)

	Pts with diabeticfoot	Pts without diabetic foot	P
n	34	37	0.75
Age	66.7 ± 8.5	66.9 ± 7.9	0.027
Sex male	16 (47.1)	15 (41.7)	0.41
Diabetes duration
< 10 yr	7 (20.6)	21 (58.3)	0.027
= 10 yr	8 (23.5)	11 (30.6)	0.045
= 20 yr	19 (55.9)	4 (11.1)	< 0.001
Treatment
Diet	4 (11.8 )	3 ( 8.3)	0.65
Oral antidiabetics	3 (8.8 )	10 (27.8)	< 0.001
Mixed	6 (17.5)	13 (36.1)	< 0.001
Insulin	21 (61.8 )	10 (27.8)	< 0.001
Smoking	7 (20.6)	9 (25)	0.71
Hypertension	20 (58.8)	25 (69.4)	0.041
Dyslipidaemia	14 (41.2)	16 (44.4)	0.35
Obesity	19 (55.9)	13 (36.1)	0.021
Chronic renal failure	15 (44.1)	13 (36.1)	0.064
Mycroalbuminuria	22 (64.7)	6 (14.7)	< 0.001
Retinopathty	19 (55.9)	36 (100)	< 0.001
PAD	10 (29.41)	9 (25)	0.54
CAD	17 ( 50)	7 (19.4)	< 0.001
TIA/Stroke	14 (41.17)	6 (16.66)	0.021
Other district atherosclerosis	28 (82.35	21 (58.33)	< 0.001
Artropathy	11 (32.4%)	2 (5.6)	< 0.001
Neuropathy	25 (73.52)	14 (38.88)	< 0.001
Diabeticfootgrade
Grade 0	1 (2.9)
Grade 1	6 (17.6)
Grade 2	8 (23.5)
Grade 3	10 (29.4)
Grade4	4 (11.8)
Grade 5	1 (2.9)
Grade 6	4 (11.8)

Data are expressed as median and interquartile (lower and upper quartile). Modified from Tuttolomondo et al[21]. PAD: Peripheral artery disease; CAD: Coronary artery disease.

Table 6 Laboratory variables in cases and controls

	Diabetic foot patients	Diabetics without foot complications	P
HbA1c	8 (7.28-9.40)	6.85 (6.10-8.00)	0.018
CRP	4 (2.25-5.15 )	2.25 (1.90-3.08)	0.041
Total cholesterol (mg/dL)	215.50 (166.50-243.00)	204.00 (185.50-210.00)	0.054
LDL cholesterol (mg/dL)	121.70 (98.75-148.75)	104.50 (78.00-123.00)	0.032
Tryglicerids (mg/dL)	160.50 (119.50-209.25)	180.50 (144.50-199.00)	0.012
Globuli bianchi	12.675 (10775.00-14140.00 )	10.700 (8850.00-12027.50)	0.032
Adiponectin (μg/mL)	7.1450 (4.47-12.17)	8.480 (5.15-12.87)	0.022
Resistin (ng/mL)	5.160 (2.96-6.29)	3.290 (2.37-6.5)	0.021
IL-6 (pg/mL)	3.21 (1.23-5.34)	2.13 (1.24-3.97 )	0.033

Demographic and anamnestic data are expressed as n° (percentage). Modified from Tuttolomondo et al[21]. HbA1c: Hemoglobin A1c; CRP: C-reactive protein; IL-6: Interleukin-6.

Table 7 Correlations of interleukin-1β, adiponectinresistin with clinical and laboratory variables in subjects with diabetic foot

Variable	Adipenectin		Resistin		IL-6
Variable	R	P values	R	P values	IL-6
Diabetes duration	0.36 (s)	< 0.001 (s)	0.09	0.37
Smoking	0.35 (s)	< 0.001 (s)	0.10	0.22
Hypertension	0.27 (s)	< 0.05 (s)	0.12	0.35
Dyslipidaemia	0.42 (s)	< 0.001 (s)	0.14	0.15
Obesity	0.13	0.42	0.12	0.22
Chronicrenalfailure	0.11	0.56	0.12	0.35
Mycroalbuminuria	0.08	0.37	0.08	0.37
Retinopathty	0.10	0. 7	0.10	0. 7
AOPC	0.11	0.81	0.10	0.77
CHD	0.46	< 0.001 (s)	0.38 (s)	< 0.0001 (s)
TIA/stroke	0.12	0.42	0.13	0.32
Other district atherosclerosis	0.15 (s)	0.42 (s)	0.14 (s)	0.36 (s)

Coefficients (R) and P values are calculated by the Pearson correlation mode. Modified from Tuttolomondo et al[21]. s: Significative; CRP: C-reactive protein; TNF-α: Tumor necrosis factor-α; IL-1β: Interleukin-1β; IL-6: Interleukin-6; IL-10: Interleukin-10; ICAM-1: Intercellular adhesion molecule-1; V-CAM-1: Vascular cell adhesion molecule-1; vWF: Von willebrand factor; TPA: Tissue plasminogen activator; PAI-1: Plasminogen activator inhibitor-1.

Table 8 Diabetic foot infection classification schemes: Infectious Diseases Society of America Infectious Diseases

Clinical description	Infectious Diseases Society of America
Wound without purulence or any manifestations of inflammation	Uninfected
≥ 2 Manifestations of inflammation (purulence or erythema, pain, tenderness, warmth, or induration); anyc ellulitis or erythemaextends 52 cm around ulcer, and infection is limited to skin or superficial subcutaneous stissues; no localcomplications or systemic illness	Mild
Infection in a patientwho is systemicallywell and metabolicall ystable buthas 2 cm; lymphangitis; spread beneath fascia; deeptissue abscess; gangrene; muscle, tendon, joint, or bone involvement	Moderate
Infection in a patient with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, hyperglycemia, or azotemia)	Severe

Adapted from Lavery et al[67].

Citation: Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop 2015; 6(1): 62-76
URL: https://www.wjgnet.com/2218-5836/full/v6/i1/62.htm
DOI: https://dx.doi.org/10.5312/wjo.v6.i1.62